Document Detail


Pravastatin for the prevention of preeclampsia in high-risk pregnant women.
MedLine Citation:
PMID:  23344286     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preeclampsia complicates approximately 3-5% of pregnancies and remains one of the major causes of maternal and neonatal morbidity. It shares pathogenic similarities with adult cardiovascular disease as well as many risk factors. Attempts at prevention of preeclampsia using various supplements and classes of medications have failed or had limited success, and they were not convincing enough to lead to widespread adoption of any particular strategy. Contrary to the experience with preeclampsia, prevention of cardiovascular mortality and other cardiovascular events in nonpregnant patients using 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors, or statins, is widely accepted. Pravastatin and other statins have been shown to reverse various pathophysiologic pathways associated with preeclampsia, such as angiogenic imbalance, endothelial injury, inflammation, and oxidative stress. These beneficial effects are likely to contribute substantially to preventing preeclampsia and provide biological plausibility for the use of pravastatin in this setting. Pravastatin has favorable safety and pharmacokinetic profiles. In addition, animal studies and human pregnancy exposure data do not support teratogenicity claims for pravastatin. Therefore, the Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network started a pilot trial to collect maternal--fetal safety data and to evaluate pravastatin pharmacokinetics when used as a prophylactic daily treatment in high-risk pregnant women (identifier NCT01717586, clinicaltrials.gov).
Authors:
Maged M Costantine; Kirsten Cleary;
Related Documents :
17916986 - Anti-phospholipid antibodies and infertility.
18190886 - Systemic lupus erythematosus and "lupus dyslipoproteinemia".
2029276 - Pregnancy outcome following first trimester exposure to chloroquine.
18720306 - Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical character...
23311886 - Maternal vitamin d status and adverse pregnancy outcomes: a systematic review and meta-...
6210866 - A study of placental transfer mechanisms in nonhuman primates using [14c]phenylalanine.
Publication Detail:
Type:  Editorial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  121     ISSN:  1873-233X     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-04-05     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  349-53     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01717586
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Female
Humans
Pravastatin / therapeutic use*
Pre-Eclampsia / prevention & control
Pregnancy
Risk Factors
Grant Support
ID/Acronym/Agency:
U10 HD047891/HD/NICHD NIH HHS; U10HD047891/HD/NICHD NIH HHS; U10HD047892/HD/NICHD NIH HHS; U10HD047905/HD/NICHD NIH HHS; U10HD057753/HD/NICHD NIH HHS; U10HD063094/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
KXO2KT9N0G/Pravastatin
Investigator
Investigator/Affiliation:
G Hankins / ; G Saade / ; M Ahmed / ; S Clark / ; W Snodgrass / ; D Flockhart / ; D Haas / ; L Haneline / ; J Renbarger / ; M Hebert / ; T Easterling / ; K Caritis / ; R Ventkataramana / ; L Brown / ; Z Ren / ; M D' Alton / ; S Thummel /
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Classification of diabetes in pregnancy: time to reassess the alphabet.
Next Document:  Surgical treatment of vaginal apex prolapse.